Format

Send to

Choose Destination
Curr Opin Rheumatol. 2009 May;21(3):211-5.

Dealing with immunogenicity of biologicals: assessment and clinical relevance.

Author information

1
Department of Rheumatology, Jan van Breemen Institute, Dr Jan van Breemenstraat 2, Amsterdam 1056 AB, The Netherlands. g.wolbink@janvanbreemen.nl

Abstract

PURPOSE OF REVIEW:

In the last decade, biologicals revolutionized rheumatology. An increasing number of patients benefit from biotherapeuticals. However, some patients do not respond to treatment and others lose their response after a certain time. Immunogenicity is one of the factors linked to secondary nonresponse but its clinical significance has remained controversial.

RECENT FINDINGS:

In recent years, knowledge of how to assess immunogenicity of biologicals has improved. Various reports show an inverse relationship between drug levels and antibody formation against the drug. Studies associated immunogenicity of therapeutic antibodies with clinically significant nonresponse in a subgroup of patients. Clinically relevant immunogenicity is influenced by several factors including dosing and concomitant medication. It has been shown that immunogenicity against biologicals can be persistent or transient.

SUMMARY:

Immunogenicity affects a significant number of patients treated with biologicals. Monitoring of drug levels as well as of antibodies against therapeutic antibodies may lead to more rational treatment strategies.

PMID:
19399992
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center